Axa's London Courtroom Setback Meets Transatlantic Expansion Push

Axa lost a GBP 677 million UK award on appeal, sold shares via a board member, and pushed ahead with a new US specialty carrier.

Axa absorbed a legal reversal in Britain and pressed ahead with a US specialty insurance build-out during a September that offered little comfort to European insurers. A broad market slump weighed on listed property-and-casualty carriers across the continent, leaving the French group with scant external tailwind to offset company-specific headwinds. The stock finished the prior session at EUR 42.56.

Appeal judges overturn GBP 677 million award

On September 15, the UK Court of Appeal ruled in favour of Santander Cards UK and Santander Insurance Services UK, setting aside an earlier award of roughly GBP 677 million that had been granted to Axa. The dispute centred on compensation claims tied to payment protection insurance policies issued before the parties concluded their agreement. Axa France IARD and Axa France Vie are the group entities affected, and the ruling removes a cash inflow the units had been counting on.

Governance sales draw scrutiny

The legal blow landed as attention also turned to dealings by the company's leadership. A mandatory disclosure published on September 25 revealed that board member Gérald Harlin had sold 36,717 Axa shares on September 21.

Berenberg stays bullish as chart holds

Not every signal pointed downward. On September 23, Berenberg reaffirmed its buy rating on the stock, pointing to the group's strategic objectives. On the price chart, the shares are holding a key technical level: the latest close sits 2.5% above the 200-day moving average of EUR 41.51. While the London judgment dimmed hopes for a earnings boost, market watchers continue to monitor the insurer's longer-term fundamentals.

New US carrier targets large brokers

Across the Atlantic, Axa is deepening its footprint in North American specialty coverage. Through its Axa XL division, the company announced the creation of Axa XL Excess & Surplus Lines Insurance Company, a dedicated US risk carrier aimed squarely at wholesale brokers. The rollout will be phased: liability business is due to begin in early 2027, with property coverage following later that same year. The structure is designed to expand capacity in the lucrative segment for non-standard industrial and commercial risks.

Leadership changes accompany the build-out

Management of the large-client division is shifting alongside the expansion. Effective October 1, Dr. Thomas Götting took on the role of Chief Client & Distribution Officer for Asia-Pacific and Europe at Axa XL, a move intended to strengthen relationships with major clients and distribution partners in those key markets.

ICC contract ends over sanctions exposure

At the same time, the group is tidying up existing commitments. According to a Reuters report, the International Criminal Court terminated its employee health insurance contract with Axa effective October 1 and switched to an unnamed provider. The parties cited risks stemming from the extraterritorial application of US sanctions as the reason for the change.

UK job cuts and a buyback to offset dilution

On the operational side, efficiency measures are underway. Media reports indicate that 60 positions at Axa Insurance UK are at risk following the earlier merger of its retail and commercial businesses, with the affected roles in risk, governance and conduct. To prevent dilution from its Shareplan 2026 employee share programme, the group has entered an agreement to repurchase and cancel its own shares, with a maximum volume of EUR 470,800,000. The transactions are to be completed by October 29 at the latest.

In today's trading, the stock is up 0.9% at EUR 42.32, putting it 2.0% above its 200-day moving average. Investors expect meaningful fundamental news on October 29, when Axa publishes its business figures for the first nine months of 2026.